2SeventyBio's partner pauses cancer therapy study after patient death (updated)

2Seventy Bio

14/06/2023 12:25

(Adds trial details from the press release in paragraphs 3 and
4, shares in paragraph 2)
       June 14 (Reuters) - 2SeventyBio  TSVT.O  on Wednesday
said its partner had paused an early-stage cancer therapy study
in response to a recent patient death in the trial.
    Shares of the cell and gene therapy firm fell about 12% to
$10.43 in premarket trading. 
    The company and partner Seattle Children's Therapeutics was
studying its experimental therapy as a treatment for children
with acute myeloid leukemia (AML), a cancer of the blood and
bone marrow.
        The fatal adverse event occurred in the first patient
treated at the second dosing level of the therapy, SC-DARIC33,
2SeventyBio said. 
    

 (Reporting by Pratik Jain; Editing by Devika Syamnath)
 ((Pratik.Jain@thomsonreuters.com;))